Skip to main content


Pronunciation: win-ZOR-uh
Generic name: calcipotriene and betamethasone dipropionate
Dosage form: cream
Drug class: Topical antipsoriatics

Medically reviewed by Carmen Pope, BPharm. Last updated on Oct 26, 2023.

What is Wynzora?

Wynzora is a once-daily, topical, fixed-dose combination cream containing calcipotriene 0.005% (a vitamin D analog) and betamethasone dipropionate 0.064% (a corticosteroid) that may be used to treat plaque psoriasis in adults 18 years of age or older.

The cream uses PAD™ Technology, which enables the mixing of oil and water using just a fraction of the emulsifier required in conventional creams and lotions. This improves the penetration, solubility, and stability of the active ingredients, the tolerability of the product, and makes it more convenient to use.

Wynzora was approved on July 22, 2020.


Use only as directed. Tell your doctor if you use other medicines or have other medical conditions or allergies.

Hypercalcemia and hypercalciuria have been observed with the use of topical calcipotriene. If either occurs, discontinue Wynzora until laboratory values of calcium normalize.

Endocrine effects

The use of high-potency steroid creams such as betamethasone dipropionate can cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency during and after withdrawal of treatment. Risk factors include the use of high-potency topical corticosteroids, use over a large surface area, or to areas under occlusion, prolonged use, altered skin barrier, liver failure, and young age. Modify use should HPA axis suppression develop.

Ophthalmic Adverse Reactions

May increase the risk of cataracts and glaucoma. If visual symptoms occur, consider referral to an ophthalmologist.

Allergic contact dermatitis

May occur with either calcipotriene or betamethasone dipropionate topical use. May be observed as a failure to heal. Confirm with diagnostic patch testing.


Use of high-potency topical steroid medicine during pregnancy may increase the risk of a low birth weight in the newborn baby. Tell your doctor if you are pregnant or plan to become pregnant.


It may not be safe to breastfeed while using Wynzora. Ask your doctor about any risks. If you apply betamethasone and calcipotriene to your chest, avoid areas that may come into contact with the baby's mouth.


Children can absorb larger amounts of this medicine through the skin and may be more likely to have side effects. Wynzora is not approved for use by anyone younger than 18 years old.

Before taking this medicine

You should not use Wynzora cream if you are allergic to calcipotriene, betamethasone dipropionate, or any other components of the cream.

Tell your doctor if you have ever had:

How should I use Wynzora?

Wynzora should be applied once daily to the plaques for up to 8 weeks. Rub in gently to ensure the plaques are saturated.

What are the side effects of Wynzora?

The most common side effects reported with Wynzora include upper respiratory tract infections, headaches, and irritation at the application site.

Postmarketing studies with topical corticosteroids have reported atrophy, striae, telangiectasias, itching, dryness, hypopigmentation, perioral dermatitis, secondary infection, and miliaria.

Ophthalmic adverse reactions of cataracts, glaucoma, and increased intraocular pressure, have been reported during the use of topical corticosteroids, including topical betamethasone products.

What happens if I miss a dose?

Apply the cream as soon as you can, but skip the missed dose if it is almost time for your next dose. Do not apply two doses at one time.

What happens if I overdose?

Seek emergency medical attention or call the Poison Help line at 1-800-222-1222 if anyone has accidentally swallowed the medicine.

High doses or long-term use of Wynzora can lead to thinning skin, easy bruising, changes in body fat (especially in your face, neck, back, and waist), increased acne or facial hair, menstrual problems, impotence, or loss of interest in sex.

What should I avoid while using Wynzora?

Avoid using other skin medications that contain betamethasone or calcipotriene. Do not use Wynzora to treat any skin condition that has not been checked by your doctor.

Avoid getting the cream in your eyes or on your face, underarms, groin area, or areas of thin skin.

Betamethasone and calcipotriene could make you sunburn more easily. Avoid sunlight or tanning beds. Wear protective clothing and use sunscreen (SPF 30 or higher) when you are outdoors.

Get emergency medical help if you have signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Side effects can occur if your skin absorbs topical steroid medicine. Tell your doctor if you have:

Also, tell your doctor if you have:

What other drugs will affect Wynzora?

Tell your doctor about all your other medicines, especially:

This list is not complete. Other drugs may affect betamethasone and calcipotriene, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible drug interactions are listed.


Active ingredients: Each gram of Wynzora cream contains 50 mcg of calcipotriene and 0.644 mg of betamethasone dipropionate. It is available in individually packed 60-gram tubes.

Inactive ingredients: isopropyl myristate, mineral oil, medium-chain triglycerides, isopropyl alcohol, polyoxyl, lauryl ether, poloxamer (407), polyoxyl 40 hydrogenated castor oil, carbomer interpolymer (type A), butylated hydroxyanisole, trolamine, dibasic sodium phosphate, heptahydrate, monobasic sodium phosphate, monohydrate, alpha-tocopherol, and purified water.


Store between 20°C-25°C (68°F-77°F) and keep away from moisture and heat. Keep the tube tightly closed when not in use. Do not freeze.

Discard unused product 6 months after the tube has been opened.


MC2 Therapeutics

Popular FAQ

Yes, Wynzora is approved to treat plaque psoriasis in adults 18 years and older. Wynzora is a cream that contains calcipotriene, a vitamin D analog, and betamethasone dipropionate, a topical corticosteroid. It is applied to the skin once daily for up to 8 weeks. Continue reading

In studies, Enstilar Foam (calcipotriene / betamethasone dipropionate) has been used safely and effectively to treat plaque psoriasis on the body and scalp in adults and adolescents ages 12 to 17 years of age. Foam preparations are often preferred by patients with scalp psoriasis (over ointments or thick creams) and the ingredients in Enstilar Foam are considered standard first-line treatments. Continue reading

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.